Search results for "antiviral agent"

showing 10 items of 505 documents

Sustained response after lamivudine treatment in HBe minus chronic hepatitis B

2004

AdultMaleHepatitis B virusHepatologybusiness.industryLamivudineMiddle AgedVirologyAntiviral AgentsText miningHepatitis B ChronicChronic hepatitisLamivudineSustained responseDNA ViralMedicineHumansFemaleHepatitis B e Antigensbusinessmedicine.drug
researchProduct

No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.

2013

OBJECTIVES: The widespread use of tumour necrosis factor (TNF)-targeted therapies in patients with rheumatic, digestive and dermatologic diseases has been associated with reports of reactivation of HBV replication and ensuing hepatitis flares both in asymptomatic HBsAg carriers and in subjects with occult HBV infection. The aim of our work was to investigate in a two-year prospective study the potential for HBV reactivation in patients with inflammatory joint diseases undergoing anti-TNF treatment from a southern Mediterranean area. METHODS: Fifty-seven consecutive outpatients attending the Academic Unit of Rheumatology at the University of Palermo (12 with rheumatoid arthritis, 17 with pso…

AdultMaleHepatitis B virusTime Factorsoccult HBV-DNAAntiviral AgentsPolymerase Chain ReactionRisk AssessmentRisk FactorsRheumatic Diseasesoccult HBV-DNA rheumatic diseases anti-TNFHumansProspective Studiesrheumatic diseaseAcademic Medical CentersHepatitis B Surface AntigensTumor Necrosis Factor-alphavirus diseasesanti-TNFMiddle AgedHepatitis Bdigestive system diseasesTreatment OutcomeItalyLamivudineAntirheumatic AgentsDNA ViralFemaleVirus ActivationBiomarkers
researchProduct

Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study

2010

To compare the management and the virological and serological efficacy of treatments for chronic hepatitis B (CHB) in HIV positive and negative patients.Two hundred and forty-six HIV positive and 205 HIV negative consecutive patients with past or present CHB, seen in October 2008 in participating departments, were included in a multicenter study. All the data were retrospectively collected from the first visit to October 2008 through a standardized questionnaire.Compared to HIV negative patients, HIV positive patients more often presented positive HBeAg (46.4% vs. 32.8%, p=0.01), HBV genotype A (54.8% vs. 17.1%, p0.0001), co-infection with HCV (12.4% vs. 5.9%, p=0.0002) or HDV (12.6% vs. 2.…

AdultMaleHepatitis B virusmedicine.medical_specialtyOrganophosphonatesHIV InfectionsAntiviral AgentsSerologyHepatitis B AntigensHepatitis B ChronicPharmacotherapyAcquired immunodeficiency syndrome (AIDS)Surveys and QuestionnairesInternal medicinemedicineHumansHepatitis B AntibodiesTenofovirSidaRetrospective StudiesHepatologybiologybusiness.industryAdeninevirus diseasesMiddle AgedHepatitis Bbiology.organism_classificationmedicine.diseaseHBeAgLentivirusImmunologyFemaleFranceViral diseasebusinessJournal of Hepatology
researchProduct

Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C

2003

Occult HBV infection in subjects with chronic hepatitis C is related to more severe disease outcome. It has been suggested that it might reduce sensitivity to antiviral treatment.To assess in HBsAg negative subjects with chronic hepatitis C any effect of the presence of HBV genomes in the liver on the early kinetics of HCV-RNA under PEG-IFN plus ribavirin.Twenty-two anti-HCV and HCV-RNA positive subjects, with biopsy-proven chronic hepatitis C (M/F 15/7; 50 +/- 8.6 years, 16 genotype 1b) were given PEG-IFN alpha 2b 1.0 microg qw plus ribavirin (800 to 1,200 mg daily according to body weight) for an intended 52 week period. Early virological response was assessed over the first 4 weeks of th…

AdultMaleHepatitis B viruspegylated interferon-alphaGenotypeBiopsyHepacivirusInterferon alpha-2Virus ReplicationAntiviral AgentsPolyethylene GlycolsHepatitis B AntibodieRibavirinchronic hepatitis CHumansHepatitis B AntibodiesAntiviral AgentHepaciviruoccult HBV infection; chronic hepatitis C; pegylated interferon-alpha; viral dynamics; treatment responseoccult HBV infectiontreatment responseInterferon-alphaAlanine TransaminaseHepatitis B viruHepatitis C AntibodiesHepatitis C ChronicMiddle AgedRecombinant ProteinViral LoadHepatitis Bviral dynamicsRecombinant ProteinsTreatment OutcomeLiverDNA ViralRNA ViralDrug Therapy CombinationFemaleHepatitis C AntibodieHuman
researchProduct

Acyclovir treatment in 2 patients with benign trigeminal sensory neuropathy

2001

AdultMaleHerpesvirus 3 Humanmedicine.medical_specialtymedicine.medical_treatmentAcyclovirAdministration OralNeurological disorderAntibodies ViralAntiviral AgentsHypesthesiamedicineHumansSimplexvirusAciclovirTrigeminal nerveChemotherapybusiness.industryAcyclic nucleosideHypoesthesiamedicine.diseaseDermatologySurgeryPeripheral neuropathyOtorhinolaryngologyTrigeminal Nerve DiseasesImmunoglobulin GSensory neuropathyFemaleSurgeryOral Surgerymedicine.symptombusinessFollow-Up Studiesmedicine.drugJournal of Oral and Maxillofacial Surgery
researchProduct

Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end-organ disease

1998

Human cytomegalovirus (HCMV)-specific antibody responses in HIV-1 infected individuals either with or without HCMV end-organ disease were examined to determine the whether development of HCMV disease was associated with a particular deficit in the antibody response. Antiwhole HCMV, anti-glycoprotein B (gB), and neutralizing antibody levels were higher in HIV-1 infected individuals than in healthy immunocompetent subjects, particularly in patients with AIDS either with or without HCMV-associated disease. Irrespective of location and spread of HCMV disease, patients who had received anti-HCMV therapy prior to sampling exhibited significantly higher anti-gB and neutralizing antibody titers tha…

AdultMaleHuman cytomegalovirusAdolescentvirusesCytomegalovirusBiologyAntibodies ViralAntiviral AgentsViral Envelope ProteinsNeutralization TestsBetaherpesvirinaeVirologyImmunopathologymedicineHumansViremiaFluorescent Antibody Technique IndirectNeutralizing antibodyAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic InfectionsAntibody titervirus diseasesbiochemical phenomena metabolism and nutritionmedicine.diseasebiology.organism_classificationVirologyCD4 Lymphocyte CountInfectious DiseasesImmunoglobulin GCytomegalovirus InfectionsImmunologyHIV-1biology.proteinFemaleViral diseaseAntibodyViral loadJournal of Medical Virology
researchProduct

Circulating intercellular adhesion molecule-1 in chronic hepatitis C patients with normal or elevated aminotransferase before and after alpha-interfe…

2001

<i>Objectives:</i> Intercellular adhesion molecule-1 (ICAM-1) plays a fundamental role during liver inflammation. In fact, weak ICAM-1 expression is physiologically restricted to the endothelium of portal vessels and to sinusoidal lining cells, but it becomes markedly evident on sinusoidal lining cells and at the surface of hepatocytes during inflammatory liver diseases. The aim of this study was to evaluate the behaviour of soluble ICAM-1 (sICAM-1) in chronic hepatitis C (CH-C) patients with persistently normal aminotransferase in comparison with patients with CH-C and elevated aminotransferase, and its changes during α-interferon (IFN) therapy. Immunohistochemical localization…

AdultMaleIntercellular Adhesion Molecule-1Alpha interferonInflammationInterferon alpha-2BiologyChronic hepatitis CAntiviral Agentsα-InterferonLiver diseaseChronic hepatitisVirologymedicineHumansAspartate Aminotransferasesα interferonInterferon-alphaAlanine TransaminaseAdhesionIntercellular adhesion molecule-1Hepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsInfectious DiseasesImmunologyCancer researchFemalemedicine.symptomLiver diseaseIntracellular
researchProduct

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin

2012

It is unclear whether the current threshold for 'high' hepatitis C virus (HCV) RNA level (800,000 IU/mL) is optimal for predicting sustained virological response (SVR). We retrospectively analysed pretreatment HCV RNA levels and SVR rates in 1529 mono-infected and 176 HIV-HCV co-infected patients treated with peginterferon alfa-2a (40 kD) plus ribavirin. We improved the threshold for differentiating low and high viral load by fitting semiparametric generalized additive logistic regression models to the data and constructing receiver operating characteristics curves. Among HCV genotype 1 mono-infected patients, the difference in SVR rates between those with low and high baseline HCV RNA leve…

AdultMaleInterferon-alphaAlanine TransaminaseHepacivirusMiddle AgedViral LoadAntiviral AgentsHepatitis CRecombinant ProteinsPolyethylene GlycolsLogistic ModelsTreatment OutcomeROC CurveRibavirinHumansRNA ViralDrug Therapy CombinationFemalehepatitis CRetrospective Studies
researchProduct

The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies

1999

Abstract Background/Aims: Cytotoxic T lymphocytes have been demonstrated in peripheral blood and liver tissue of patients with chronic hepatitis C virus infection, but their significance for viral clearance is unknown. Therefore, we analyzed hepatitis C virus-specific cytotoxic T lymphocyte precursor frequencies in chronic hepatitis C virus carriers during interferon-α treatment. Methods: Blood mononuclear cells or CD8+ T cells from HLA-A2 positive and negative patients and controls were analyzed in chromium-release assays using a panel of 18 synthetic peptides from the HCV core, E1 and NS4 antigens bearing HLA-A2 binding motifs. Specific cytotoxic T lymphocyte precursor frequencies were st…

AdultMaleMetabolic Clearance RateHepatitis C virusBiologymedicine.disease_causeAntiviral AgentsAntigenInterferonHLA-A2 AntigenmedicineHumansCytotoxic T cellHepatologyELISPOTInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseVirologyTreatment OutcomeCase-Control StudiesImmunologyFemaleViral loadCD8T-Lymphocytes Cytotoxicmedicine.drugJournal of Hepatology
researchProduct

Quantification of DNA in Plasma by an Automated Real-Time PCR Assay (Cytomegalovirus PCR Kit) for Surveillance of Active Cytomegalovirus Infection an…

2008

ABSTRACT The performance of a plasma real-time PCR (cytomegalovirus [CMV] PCR kit; Abbott Diagnostics) was compared with that of the antigenemia assay for the surveillance of active CMV infection in 42 allogeneic hematopoietic stem cell transplantation (Allo-SCT) recipients. A total of 1,156 samples were analyzed by the two assays. Concordance between the two assays was 82.2%. Plasma DNA levels correlated with the number of pp65-positive cells, particularly prior to the initiation of preemptive therapy. Fifty-seven episodes of active CMV infection were detected in 37 patients: 18 were defined solely by the PCR assay and four were defined on the basis of the antigenemia assay. Either a cutof…

AdultMaleMicrobiology (medical)Adolescentmedicine.medical_treatmentCongenital cytomegalovirus infectionCytomegalovirusHematopoietic stem cell transplantationmedicine.disease_causeAntiviral AgentsChemopreventionPolymerase Chain ReactionSensitivity and SpecificityHerpesviridaelaw.inventionViral Matrix ProteinsPlasmalawBetaherpesvirinaeVirologymedicineHumansAntigens ViralPolymerase chain reactionAgedbiologyHematopoietic Stem Cell Transplantationvirus diseasesMiddle AgedViral LoadPhosphoproteinsmedicine.diseasebiology.organism_classificationVirologyReal-time polymerase chain reactionROC CurveCytomegalovirus InfectionsDNA ViralImmunologyFemaleViral diseaseViral loadJournal of Clinical Microbiology
researchProduct